Meeting
2020 ASCO Virtual Scientific Program
Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.
Authors
Sun Young Rha
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
Sun Young Rha , Seung-Hoon Beom , Young Geun Shin , Dong-Seok Yim , Yong Wha Moon , Tae Won Kim , Sun Young Kim , Gun Min Kim , Hyo Song Kim , Jae-Ho Cheong , Young Woo Lee , Barbara Jean Geiger , Sanghee Yoo , Marc S. Rudoltz , Filip Janku
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT03272256
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3590)
DOI
10.1200/JCO.2020.38.15_suppl.3590
Abstract #
3590
Poster Bd #
320
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase 1 study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors.
First Author: Sun Young Rha
Poster
2022 ASCO Annual Meeting
Phase 1 study of SGN-B7H4V, a novel, investigational vedotin antibody–drug conjugate directed to B7-H4, in patients with advanced solid tumors (SGNB7H4V-001, trial in progress).
First Author: Amita Patnaik
Poster
2018 ASCO Annual Meeting
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).
First Author: Andrew J. Wagner
Poster
2018 ASCO Annual Meeting
A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.
First Author: Ruihua Xu